We found that i) IFN-I signaling in donor hematopoietic and T cells does not influence GVHD after allo-HSCT and ii) targeted therapy of RIG-I ameliorates GVHD independent of IFN-I signaling in donor hematopoietic and T cells. This evidence concerns the gene RIGI and graft versus host disease.